Cite
Ohka S, Yamada S, Nishizawa D, et al. Heparan sulfate 3-. Mol Pain. 2021;17:17448069211052171doi: 10.1177/17448069211052171.
Ohka, S., Yamada, S., Nishizawa, D., Fukui, Y., Arita, H., Hanaoka, K., Iseki, M., Kato, J., Ogawa, S., Hiranuma, A., Kasai, S., Hasegawa, J., Hayashida, M., Fukushi, S., Saijo, M., & Ikeda, A. K. (2021). Heparan sulfate 3-. Molecular pain, 1717448069211052171. https://doi.org/10.1177/17448069211052171
Ohka, Seii, et al. "Heparan sulfate 3-." Molecular pain vol. 17 (2021): 17448069211052171. doi: https://doi.org/10.1177/17448069211052171
Ohka S, Yamada S, Nishizawa D, Fukui Y, Arita H, Hanaoka K, Iseki M, Kato J, Ogawa S, Hiranuma A, Kasai S, Hasegawa J, Hayashida M, Fukushi S, Saijo M, Ikeda AK. Heparan sulfate 3-. Mol Pain. 2021 Jan-Dec;17:17448069211052171. doi: 10.1177/17448069211052171. PMID: 34904858.
Copy
Download .nbib